Ligand Pharmaceuticals Hits New 52-Week High of $266.87

Ligand Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 266.87 on June 17, 2026. This achievement underscores the company's robust performance in the pharmaceuticals and biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 3,898 million. Over the past year, Ligand Pharmaceuticals has demonstrated impressive growth, with a remarkable 230.87% increase in stock price compared to the S&P 500's 24.03% performance. The company has reported positive results for the last three consecutive quarters, showcasing a strong operating cash flow of USD 123.57 million and a net profit of USD 36.68 million, which has grown by 157.25%. Ligand's financial metrics reflect its solid position in the market, with a price-to-earnings ratio of 68.00 and a price-to-book value of 3.83. Additionally, the company maintains a net-debt-free status and boasts high institutional holdings at 100%, indicating strong confidence from institutional investors. With these indicators, Ligand Pharmaceuticals continues to solidify its standing in the competitive biotechnology landscape.